The 2023 multisociety Delphi consensus redefined the nomenclature for steatotic liver disease (SLD) by replacing nonalcoholic fatty liver disease with metabolic dysfunction-associated steatotic liver disease (MASLD) and introducing metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD). This revised framework is expected to enhance epidemiological surveillance, phenotyping of SLD, and public health interpretation. This review summarizes contemporary literature on the global epidemiology, disease burden, and comparative outcomes of MASLD, MetALD, and ALD. MASLD remains the most prevalent SLD subtype, affecting approximately 30–40% of adults worldwide, with a rising burden over time. MASLD rapidly increases in regions with lower sociodemographic indices. MetALD affects an estimated 2–8% of adults and represents an important overlap phenotype, although its prevalence is likely underestimated due to frequent underreporting of alcohol intake. ALD has a lower prevalence but contributes disproportionately to higher liver-related morbidity and mortality and is reported to have a marked regional variation linked to patterns of alcohol consumption. SLD has emerged as a major global epidemic, with MASLD imposing the greatest population burden and MetALD/ALD disproportionately contributing to severe liver-related outcomes. Across SLD phenotypes, cardiovascular disease is a major cause of death in non-cirrhotic disease, while liver-related outcomes show a gradient associated with alcohol exposure. Significant epidemiologic limitations include heterogeneity in the steatosis assessment methods, limited availability of cardiometabolic criteria, and reliance on self-reported alcohol consumption. Mitigating this growing burden of SLD requires public health policies that incorporate metabolic risk prevention, regulation of alcohol consumption, and early risk stratification.
Citations
Citations to this article as recorded by
Placebo-Arm Cirrhosis Incidence in Fibrotic MASH: A Trial-Based Benchmark Matheus Souza Digestive Diseases and Sciences.2026;[Epub] CrossRef
Starving in Plenty: Recognizing Malnutrition in Steatotic Liver Disease Hyun Hee Sul, Saeed Ahmad, Matheus Souza Digestive Diseases and Sciences.2026;[Epub] CrossRef
Association of a Reported Penicillin Allergy Label With Clinical Outcomes in Alcohol‐Associated Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Kanyaphak Charnpatanakorn, Preenapun Saokhieo, Ben Thiravetyan, Allan Bueso, Ahmad Anouti, Apichat Kaewdech, Surapon Nochaiwong, Luis Antonio Díaz, Juan Pablo Arab, Jonathan A. Bernstein, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.1072. CrossRef
Alcohol-aware risk stratification and subtype-specific care pathways across metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Hyo Young Lee, Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0659. CrossRef
PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five‐Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Seung Up Kim, Su Jong Yu, Pil Soo Sung Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Reaffirming the role of SGLT2 inhibitors in slowing fibrotic progression in MASLD: Correspondence to editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction- Jonggi Choi, Raymond T. Chung Clinical and Molecular Hepatology.2026; 32(3): e369. CrossRef
Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial Jiajia Mai, Hong Zhang, Min Wu, Meng Yu, Kui Liu, Guixia Wang, Yanhua Ding Diabetology & Metabolic Syndrome.2026;[Epub] CrossRef
Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review Boknyun Kim, Joseph Kim, Grace Kim, Kitai Kim Pharmaceuticals.2026; 19(10): 1572. CrossRef
Correspondence to editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e219. CrossRef
Correspondence to editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2026; 32(1): e87. CrossRef
Background/Aims Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus. The purpose of this assessment was to establish proof of concept in liver histologic improvement with HTD1801 treatment based on preclinical and clinical evidence.
Methods The efficacy of HTD1801 was evaluated in a preclinical MASH/dyslipidemia model (golden hamsters fed a high fat diet, eight/group) after six weeks of daily treatment. Additionally, in a secondary analysis of a Phase 2 clinical study, 100 patients with presumed MASH were evaluated by multiple noninvasive markers associated with MASH resolution and/or fibrosis improvement. These include magnetic resonance imaging proton density fat fraction (MRIPDFF; ≥30% LFC reduction), iron-corrected T1 (≥80 ms reduction), alanine aminotransferase (≥17 U/L reduction), weight loss (≥5% reduction), Fibrosis-4 index (shift to <1.3), and MASH resolution index (achieving ≥–0.67).
Results Preclinical findings in the MASH/dyslipidemia hamster model showed that HTD1801 significantly improved histologic fibrosis and the Nonalcoholic Fatty Liver Disease Activity Score to such a degree that improvements approximated the appearance of the normal controls. In the clinical study, 52% of HTD1801-treated patients achieved MRI response criteria compared to 24% of placebo (p<0.05). Dose-dependent improvements were observed across biomarkers, with more HTD1801-treated patients achieving response criteria associated with improvements in the histologic features of MASH.
Conclusions These findings suggest that HTD1801 has strong potential to produce histological improvements in patients with MASH.
Citations
Citations to this article as recorded by
Activation of Sirtuin 3, a Promising “Head Goose Molecule,” Triggers the Negentropic Mechanism for Treating Metabolic Diseases Hu Li, Tong Wang, Biao Dong, Zonggen Peng, Jiandong Jiang Engineering.2026; 60: 294. CrossRef
Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Young Chang, Yong Kyun Cho, Young Seok Kim, Sung-Eun Kim, Gab Jin Cheon, Ji Hoon Kim, Hyun Yang, Won Kim, Sang Bong Ahn, Eileen L. Yoon, Jae Youn Cheong, Jin-Woo Lee, Moon Young Kim, Hyung Joon Kim, Sae Hwan Lee, Eun Young Cho, Na Ryung Choi, Hye Won Lee, Journal of Korean Medical Science.2026;[Epub] CrossRef
An overview on phytotherapeutics for metabolic syndrome: A journey from traditional knowledge to modern clinical validation Dolly Rani, Sandip Chatterjee, Pawan Kumar Goswami Journal of Diabetes & Metabolic Disorders.2026;[Epub] CrossRef
Mapping the global research output of Traditional Chinese Medicine in the treatment of metabolic dysfunction-associated steatotic liver disease: a comprehensive bibliometric analysis based on multiple databases (2000–2025) Da Wang, Mengwei Li, Rongting Zhao, Hui Wang, Hang Chen, Minshan Huang, Yingxue Shen, Lanqing Ma Frontiers in Medicine.2026;[Epub] CrossRef
Comparative efficacy of phase 2–3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis Tsubasa Tsutsumi, Nicole Shu Ying Tang, Cheng Han Ng, Hiroyuki Suzuki, Nicholas L. Syn, N. Apoorva Sasikumar, Glenn Jun Kit Ho, Damien Chua, Jing Kai Tioh, Thanawin Pramotedham, Selvakumar Vigneshwaran, Peter Jin Sun Low, Joon Ho Moon, Dan Yock Young, Vin Med.2026; 7(5): 101077. CrossRef
Regulation of bile acids homeostasis: a feasible and versatile way to treat or diagnose liver disorders Qian-Qian Wu, Le-Ying Gao, Hui-Yi Feng, Hao-Lin Liu, Hui Gao, Wei Peng, Nan Li Frontiers in Nutrition.2026;[Epub] CrossRef
“Surrogates without substance?” Questioning the evidence for histologic improvement with HTD1801: Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a p Zhihao Lei Clinical and Molecular Hepatology.2026; 32(2): e158. CrossRef
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study” Xi-Lin Gao Clinical and Molecular Hepatology.2026; 32(2): e161. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Berberine from Traditional Chinese Medicine in Liver Diseases: From Steatosis to Fibrosis and Hepatic Malignancies Hongxia He, Shuyun Wu, Jiazhi Yi The American Journal of Chinese Medicine.2026; 54(06): 1721. CrossRef
The liver in diabetes: current state and future perspectives Hannele Yki-Järvinen, Michael Roden Diabetologia.2026; 69(11): 3021. CrossRef
Berberine as a multitarget modulator of metabolic inflammation: molecular mechanisms, circadian regulation, and translational perspectives Jiaxuan Xie, Junbo Cao, Shuying Zhang, Jiayang Zhang, Guanlin Wu, Xinyu Qiu, Lihong Chen, Guangrui Yang Frontiers in Pharmacology.2026;[Epub] CrossRef
Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review Boknyun Kim, Joseph Kim, Grace Kim, Kitai Kim Pharmaceuticals.2026; 19(10): 1572. CrossRef
Berberine and metabolic dysfunction-associated steatotic liver disease: a global analysis of molecular mechanisms, translational challenges and research frontiers Fei Yu, Sihan Yin, Jiayu Zhu, Kewei Sun Frontiers in Nutrition.2026;[Epub] CrossRef
Molecular mechanisms and clinical applications of gut microbiota-derived bioactive compounds in metabolic dysfunction-associated fatty liver disease Chengyun Ma, Jing Wang, Xuanli Song, Xue Wang, Shuai Zong Frontiers in Immunology.2025;[Epub] CrossRef
A demethylation chloroisosulochrin and a chromone metabolite from the endophytic fungus
Penicilium
sp.
Ke-Liang Chen, Xue Wang, Yang Liu, Yun-Bao Liu Journal of Asian Natural Products Research.2026; 28(8): 1152. CrossRef
L. acidophilus prevents cholesterol gallstones in mice by regulating gut microbiota-mediated BAs metabolism and cholesterol homeostasis Mengyan Du, Lvwang Ye, Cong Wang, Ting Jiang, Fang Liu Journal of Functional Foods.2026; 139: 107194. CrossRef
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef
Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Nahee Hwang, Sungsoon Fang Clinical and Molecular Hepatology.2025; 31(2): e228. CrossRef
Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post‐Radiofrequency Ablation Yuezhan Shan, Hongyu Chu, Sheyu Ye, Guofeng Ji, Jiayi Zhao, Xinghui Si, Yumin Zhong, Youmao Tao, Jingwei Shi, Xuedong Fang Advanced Science.2025;[Epub] CrossRef
Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): e226. CrossRef
Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): e226. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
Background/Aims Metabolic dysfunction-associated steatohepatitis (MASH) is a significant risk factor for gallstone formation, but mechanisms underlying MASH-related gallstone formation remain unclear. Golgi membrane protein 1 (GOLM1) participates in hepatic cholesterol metabolism and is upregulated in MASH. Here, we aimed to explore the role of GOLM1 in MASH-related gallstone formation.
Methods The UK Biobank cohort was used for etiological analysis. GOLM1 knockout (GOLM1-/-) and wild-type (WT) mice were fed with a high-fat diet (HFD). Livers were excised for histology and immunohistochemistry analysis. Gallbladders were collected to calculate incidence of cholesterol gallstones (CGSs). Biles were collected for biliary lipid analysis. HepG2 cells were used to explore underlying mechanisms. Human liver samples were used for clinical validation.
Results MASH patients had a greater risk of cholelithiasis. All HFD-fed mice developed MASH, and the incidence of gallstones was 16.7% and 75.0% in GOLM1-/- and WT mice, respectively. GOLM1-/- decreased biliary cholesterol concentration and output. In vivo and in vitro assays confirmed that GOLM1 facilitated cholesterol efflux through upregulating ATP binding cassette transporter subfamily G member 5 (ABCG5). Mechanistically, GOLM1 translocated into nucleus to promote osteopontin (OPN) transcription, thus stimulating ABCG5-mediated cholesterol efflux. Moreover, GOLM1 was upregulated by interleukin-1β (IL-1β) in a dose-dependent manner. Finally, we confirmed that IL-1β, GOLM1, OPN, and ABCG5 were enhanced in livers of MASH patients with CGSs.
Conclusions In MASH livers, upregulation of GOLM1 by IL-1β increases ABCG5-mediated cholesterol efflux in an OPN-dependent manner, promoting CGS formation. GOLM1 has the potential to be a molecular hub interconnecting MASH and CGSs.
Citations
Citations to this article as recorded by
Methylation changes of gallbladder DNA during the formation of gallstones Hongyu Xu, Jinlong Hu, Jinshan Liu, Rui Wang, Junbin Peng, Peilin Liu, Jiaming Yao, Baoqiang Cao Epigenomics.2026; 18(1): 55. CrossRef
Biliary elimination of cholesterol can be modulated by hepatocyte mitochondrial Aquaporin-8 in mice María Celeste Capitani, Alejo M. Capiglioni, Raúl A. Marinelli, Julieta Marrone Scientific Reports.2026;[Epub] CrossRef
Anti-Obesity Effects of Pear Extract (Pyrus pyrifolia): Clinical Implications and Therapeutic Potential Yong Kyun Roh, Yoon-su Ha, Taek-kyong Kim, Kyungseok Kim, Soo Ro Kim, Da Hee Kim, Seonghwan Hwang, Se-Ran Yang, Sunbok Jang, Seung-Jin Kim International Journal of Stem Cells.2026; 19(2): 242. CrossRef
Integrated multi-omics profiling identifies genetic loci of African swine fever resistance in pigs Xiaowei Ye, Qinqin Xie, Caiyun Cao, Shuang Liu, Wenbo Sun, Zhe Zhang, Qishan Wang, Yuchun Pan, Zhen Wang GigaScience.2026;[Epub] CrossRef
Integrating bioinformatics and machine learning to analyze molecular biomarkers, immune infiltration mechanisms, and small-molecule therapeutic candidates for gallstones Zhixing Wei, Yuting Pang, Yun Qiao, Zhigang Wei Letters in Drug Design & Discovery.2026; 23(5): 100394. CrossRef
Association of arm circumference with the prevalence of gallstones in United States adults: a retrospective analysis on US National Health and Nutrition Examination Survey Jianjun Wang, Xi Chen, Wei He, Xintao Zeng, Pei Yang, Jianping Gong, Decai Wang Frontiers in Medicine.2025;[Epub] CrossRef
Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Nahee Hwang, Sungsoon Fang Clinical and Molecular Hepatology.2025; 31(2): e228. CrossRef
Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): 628. CrossRef
Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Nahee Hwang, Sungsoon Fang Clinical and Molecular Hepatology.2025; 31(2): 631. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef
Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): e226. CrossRef
Pharmacological effects and prospects of traditional Chinese medicine and its bioactive components in the prevention and treatment of urolithiasis and cholelithiasis Dan Jiang, Xiaofeng Zhou, Xiaolong Lu Letters in Drug Design & Discovery.2025; 22(12): 100274. CrossRef
Background/Aims Metabolic dysfunction-associated steatohepatitis (MASH) is an unmet clinical challenge due to the rapid increased occurrence but lacking approved drugs. Autophagy-related protein 16-like 1 (ATG16L1) plays an important role in the process of autophagy, which is indispensable for proper biogenesis of the autophagosome, but its role in modulating macrophage-related inflammation and metabolism during MASH has not been documented. Here, we aimed to elucidate the role of ATG16L1 in the progression of MASH.
Methods Expression analysis was performed with liver samples from human and mice. MASH models were induced in myeloid-specific Atg16l1-deficient and myeloid-specific Atg16l1-overexpressed mice by high-fat and high-cholesterol diet or methionine- and choline-deficient diet to explore the function and mechanism of macrophage ATG16L1 in MASH.
Results Macrophage-specific Atg16l1 knockout exacerbated MASH and inhibited energy expenditure, whereas macrophage-specific Atg16l1 transgenic overexpression attenuated MASH and promotes energy expenditure. Mechanistically, Atg16l1 knockout inhibited macrophage lipophagy, thereby suppressing macrophage β-oxidation and decreasing the production of 4-hydroxynonenal, which further inhibited stimulator of interferon genes(STING) carbonylation. STING palmitoylation was enhanced, STING trafficking from the endoplasmic reticulum to the Golgi was promoted, and downstream STING signaling was activated, promoting proinflammatory and profibrotic cytokines secretion, resulting in hepatic steatosis and hepatic stellate cells activation. Moreover, Atg16l1-deficiency enhanced macrophage phagosome ability but inhibited lysosome formation, engulfing mtDNA released by pyroptotic hepatocytes. Increased mtDNA promoted cGAS/STING signaling activation. Moreover, pharmacological promotion of ATG16L1 substantially blocked MASH progression.
Conclusions ATG16L1 suppresses MASH progression by maintaining macrophage lipophagy, restraining liver inflammation, and may be a promising therapeutic target for MASH management.
Citations
Citations to this article as recorded by
ATG16L1 Regulates Reparative Function of Peritoneal Macrophages During Acute Drug-induced Liver Injury Xun Wang, Xinyu Zhan, Yiyun Gao, Hao Wang, Zheng Liu, Mu Liu, Ling Lu, Haoming Zhou Cellular and Molecular Gastroenterology and Hepatology.2026; 20(2): 101674. CrossRef
Ferroptosis inhibits cementoblast mineralization via cGAS-STING/GPX4 axis Tian Wei, Dongyang Li, Jie Zhang, Zhe Zhou, Chunmiao Jiang Progress in Orthodontics.2026;[Epub] CrossRef
Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk Qiqi Zhao, Shengwen Lu, Yu Guan, Zhiwen Sun, Shi Qiu, Aihua Zhang Lipids in Health and Disease.2026;[Epub] CrossRef
VAMP4/STX8 Mediate the Autophagic Secretion of Mitochondria and Promote TAMs Polarization in HNSCC Jingcun Shi, Chun Liu, Xiaoning Wang, Chuwen Li, Zhen Zhang, Ming Yan, Haiyan Guo, Jianjun Zhang Journal of Extracellular Vesicles.2026;[Epub] CrossRef
CRISPLD2 protects against liver inflammation and fibrosis via GRP78 to repress HMGB1/TLR4 axis–mediated STING palmitoylation Haoye Zhang, Juan Wang, Hui Yang, Yu Yan, Jiafeng Zou, Zhenguo Liu Hepatology Communications.2026;[Epub] CrossRef
Mechanisms and therapeutic potential of the cGAS–STING signaling pathway in macrophage activation and polarization Hua Liu, Xucheng Zhu, Jie Wang, Xinlei Yao, Zhanzhan Li, Chuli Zhu, Jiacheng Sun, Xia Li, Lei Qi, Hualin Sun Biochemical Pharmacology.2026; 250: 118031. CrossRef
ZDHHC17-mediated IKKβ palmitoylation suppresses NF-κB signaling to mitigate the progression of liver fibrosis Bin Fan, Meng Yi, Xiaolong Zhong, Shilin Li, Chunhui Yang, Peng Zhang, Daping Song, Qing Xiao, Yujia Li, Xiaoqiong Duan, Limin Chen iScience.2026; 29(7): 116360. CrossRef
LGALS3 signaling and macrophage ferroptosis in steatohepatitis Wei Liu, Zhuo-Jin Shi World Journal of Hepatology.2026;[Epub] CrossRef
The endo-lysosomal–lipid axis: bidirectional interactions between membrane trafficking dysfunction and lipid metabolic disorders Yao Du, Li Li, Mingtao Du, Zhi Xu, Xiaorong Zhang, Wa Cao Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Macrophage lipophagy in atherosclerosis: from molecular mechanisms to traditional Chinese medicine interventions Ying Hu, Shuo Yuan, Xingjuan Chen, Yu Wen, Fang Liu, Xuewei Dong, Mengxuan Cui, Na Zhao, Hua Dong Frontiers in Pharmacology.2026;[Epub] CrossRef
Lipid metabolism: a potential checkpoint for cGAS-STING regulation in colorectal cancer Qi Qiu, Zhihong Cheng, Jian Gu, Tao Zhang, Mingdong Cai, Jiliang Wang Frontiers in Immunology.2026;[Epub] CrossRef
The cGAS-STING pathway: mechanistic basis, dual biological functions and translational therapeutic advances Minjue Shan, Yan Liao, Ziyou Lin, Lizhou Song, Wangzheqi Zhang, Ruoyu Jiang, Haoling Zhang, Yadong Guo, Fei Su Apoptosis.2026;[Epub] CrossRef
Microbiota-derived SCFAs modulate Socs36E-mediated feedback to regulate intestinal stem cell proliferation upon Atg4 loss in Drosophila Ping Wang, Xianhao Li, Wendong Liu, Jiewei Wang, Li Hua Jin Stem Cell Reports.2026; : 103117. CrossRef
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling Ying He, Tianyi Ma, Hanying Xing, Xinming Cao, Fanfan Song, Yongning Pan, Luping Ren European Journal of Pharmacology.2026; 1037: 179418. CrossRef
Macrophage ATG16L1 promotes liver regeneration after partial hepatectomy Xinyu Zhan, Yan Bai, Qing Zhu, Yiyun Gao, Fan Li, Qingfa Bu, Zeyu Zhu, Zhuqing Rao, Haoming Zhou JHEP Reports.2025; 7(5): 101330. CrossRef
Unveiling the crossroads of STING signaling pathway and metabolic reprogramming: the multifaceted role of the STING in the TME and new prospects in cancer therapies Siwei Wang, Lu Qin, Furong Liu, Zhanguo Zhang Cell Communication and Signaling.2025;[Epub] CrossRef
ATG16L1 restrains macrophage NLRP3 activation and alveolar epithelial cell injury during septic lung injury Yan Bai, Xinyu Zhan, Qing Zhu, Xingyue Ji, Yingying Lu, Yiyun Gao, Fei Li, Zhu Guan, Haoming Zhou, Zhuqing Rao Clinical and Translational Medicine.2025;[Epub] CrossRef
BMDM-derived ORP8 suppresses lipotoxicity and inflammation by relieving endoplasmic reticulum stress in mice with MASH Yi Chen, Kangjie Xie, Caiyang Chen, Xihui Wang, Chenchen Ma, Zhangxiang Huang, Yingfu Jiao, Weifeng Yu Molecular Medicine.2025;[Epub] CrossRef
Lipophagy in immune cells and immune response modulation: Mechanisms and therapeutic potential Yiwei Shang, Jun Yuan, Shaoting Wang, Wenfang He, Binqi Wang, Danna Zheng, Nan Yang, Juan Jin, Qiang He International Immunopharmacology.2025; 162: 115172. CrossRef
Role of S-palmitoylation in digestive system diseases Hanqing Li, Qiuxiang Yuan, Shuangshuang Wang, Tao Yu, Xingsi Qi Cell Death Discovery.2025;[Epub] CrossRef
Interplay of cGAS-STING and ferroptosis: crosstalk, molecular mechanisms, and therapeutic prospects Yumin Wang, Shuang Wu, Yitong Wang, Clara Xi Wang, Weihua Zheng, Xia Yun, Zhiji Wang, Junjing Zhang, Lida Du, Hongquan Wang Archives of Toxicology.2025; 99(12): 4883. CrossRef
Protein palmitoylation: an emerging regulator of inflammatory signaling and diseases Rong Chen, Xiaohua Tang, Ying Wang, Bo Wang, Fei Mao Frontiers in Immunology.2025;[Epub] CrossRef
Metabolism-driven posttranslational modifications and immune regulation: Emerging targets for immunotherapy Gujie Wu, Xiaofei Fan, Lin Cheng, Zongwei Chen, Yanjun Yi, Jiaqi Liang, Xiaolong Huang, Na Yang, Jiacheng Yin, Weigang Guo, Yiwei Huang, Shanye Yin Science Advances.2025;[Epub] CrossRef
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy” Junjie Yu Clinical and Molecular Hepatology.2024; 30(4): 721. CrossRef
Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy” Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu Clinical and Molecular Hepatology.2024; 30(4): 1026. CrossRef
First
Prev
